The PE Ratio as of September 2024 (TTM) for Larimar Therapeutics, Inc. (LRMR) is -7.19

According to Larimar Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -7.19. This represents a change of 33.64% compared to the average of -5.38 of the last 4 quarters.

Larimar Therapeutics, Inc. (LRMR) Historical PE Ratio (quarterly & annually)

How has LRMR PE Ratio performed in the past?

The mean historical PE Ratio of Larimar Therapeutics, Inc. over the last ten years is -4.11. The current -7.19 PE Ratio has changed 17.38% with respect to the historical average. Over the past ten years (40 quarters), LRMR's PE Ratio was at its highest in in the December 2014 quarter at 0. The PE Ratio was at its lowest in in the March 2019 quarter at -5588.18.

Larimar Therapeutics, Inc. (LRMR) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Larimar Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Larimar Therapeutics, Inc. (LRMR) Average PE Ratio

How has LRMR PE Ratio performed in the past?

The current PE Ratio of Larimar Therapeutics, Inc. (LRMR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Larimar Therapeutics, Inc. (LRMR) PE Ratio vs. Peers

How is LRMR’s PE Ratio compared to its peers?

Larimar Therapeutics, Inc.’s PE Ratio is greater than Vaxcyte, Inc. (-26.31), less than Syndax Pharmaceuticals, Inc. (-6.17), greater than Merus N.V. (-18.45), less than Sutro Biopharma, Inc. (-2.69), less than Immuneering Corporation (-0.62), greater than Centessa Pharmaceuticals plc (-9.93), less than Celcuity Inc. (-7.01), less than Ikena Oncology, Inc. (-1.22), less than Spero Therapeutics, Inc. (4.06), less than Bolt Biotherapeutics, Inc. (-0.37), less than Coherus BioSciences, Inc. (-4.85), greater than Gracell Biotechnologies Inc. (-12.26), less than Neoleukin Therapeutics, Inc. (-0.98), less than Surrozen, Inc. (-0.55), greater than Keros Therapeutics, Inc. (-11.28), less than Kezar Life Sciences, Inc. (-0.41), less than Cabaletta Bio, Inc. (-2.34), less than Homology Medicines, Inc. (-0.01), greater than Day One Biopharmaceuticals, Inc. (-7.39), less than Alector, Inc. (-2.92),

Build a custom stock screener for Larimar Therapeutics, Inc. (LRMR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Larimar Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Larimar Therapeutics, Inc. (LRMR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Larimar Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.